Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Cypress, California 90630


This is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ACE-011 in healthy postmenopausal women.


Inclusion Criteria: 1. Subject is a postmenopausal woman, 45-85 years old (inclusive). 2. Subject has had 12 months of spontaneous amenorrhea, OR 6 months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels >40 IU/L OR is 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy. 3. Subject is taking at least 500 mg of calcium supplement and 400 IU of vitamin D daily and has been following this regimen for at least 4 weeks prior to the first dose of study drug administration. 4. Subject has a body mass index (BMI) of ≥ 18.5 to < 30. 5. Subject must give written informed consent. If required by local law, candidates must also authorize the release and use of protected health information (PHI). Exclusion Criteria: 1. Subject has a history of clinically significant major disease (as determined by the Investigator). 2. Subject has a history of hyperparathyroidism, hypoparathyroidism, hypocalcemia, rheumatoid arthritis, myeloproliferative disorder, gout, Paget's disease of the bone, or osteomalacia. 3. Subject has had a long bone fracture within the past 6 months prior to enrollment, or an osteoporosis-related fracture within the previous 2 years. 4. Subject has a history of opportunistic infection, or has had a serious local or systemic infection within 3 months prior to screening. 5. Subject has a history of severe allergic or anaphylactic reactions. 6. Subject had major surgery within the previous 3 months. 7. Subject has a history of drug or alcohol abuse, or tests positive in a drug and alcohol screen at screening or on Day 1 prior to dosing. 8. Subject consumed any alcohol within 72 hours prior to dosing. 9. Subject gave a blood donation (one unit or more) within 1 month prior to dosing, or plans to give a blood donation during the course of the study. 10. Subject has taken any of the following bone active medications: - Teriparatide at any time in their lifetime. - Fluoride therapy for more than 3 months during the previous 2 years. - Estrogen, androgen, anabolic steroids, corticosteroids (excluding inhaled, topical or local injections for joint pain), calcitonin, or other bone active drugs (e.g. selective estrogen receptor modulators) within the 4 months prior to screening. Bisphosphonates: - If treated for more than 6 months at any time in their lifetime. - If treated for 3 to 6 months within 2 years of screening. - If treated for less than 3 months within 6 months of screening. 11. Subjects with chronic stable diseases including migraines, hypertension, hyperthyroid disorder, hypothyroid disorder, gastroesophageal reflux disease, or mild depression/anxiety will be excluded unless the investigator does not have safety or compliance concerns at study entry.



Primary Contact:

Principal Investigator
Michelle Ababa, MD
West Coast Clinical Trials

Backup Contact:


Location Contact:

Cypress, California 90630
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.